Similar to the examples the company shared in the last presentation, this avenue limits dilution compared to giving up 90-100% of the company to BP for cash milestone payments and single digit royalties which a number of small companies do.
Since a number of the assets are further along (i.e. Phase II) that further reduced dilution and is more attractive to new investors.
(4)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links